Asthma costs and social impact

 
Carlos Nunes, Ana Margarida Pereira and Mário Morais-Almeida

Abstract

In recent decades, both asthma prevalence and incidence have been increasing worldwide, not only due to the genetic background, but mainly because of the effect of a wide number of environmental and lifestyle risk factors.

In many countries noncommunicable diseases, like asthma, are not yet considered a healthcare priority. This review will analyze and discuss disparities in asthma management in several countries and regions, such as access to healthcare human resources and medications, due to limited financial capacity to develop strategies to control and prevent this chronic disease.

This review tries to explore the social and economic burden of asthma impact on society. Although asthma is generally accepted as a costly illness, the total costs to society (direct, indirect and intangible asthma costs) are difficult to estimate, mainly due to different disease definitions and characterizations but also to the use of different methodologies to assess the asthma socio-economic impact in different societies.

The asthma costs are very variables from country to country, however we can estimate that a mean cost per patient per year, including all asthmatics (intermittent, mild, moderate and severe asthma) in Europe is $USD 1,900, which seems lower than USA, estimated mean $USD 3,100.

Download PDF

 

 

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma Top story: United Action for Allergy and Asthma https://t.co/Bssbmnu3cF, see more https://t.co/CpGiFuOOYd
1hreplyretweetfavorite
Interasma RT @Aller_MD: Top story: United Action for Allergy and Asthma https://t.co/xdIbmmWD5j, see more https://t.co/jgCeENQuZt
3hreplyretweetfavorite
Interasma RT @ARIAGuideline: Emerging technologies for predictive medicine in chronic airway diseases... https://t.co/1uOqcIwQ1o
3hreplyretweetfavorite
Interasma RT @Aller_MD: “Global Market Study on AR: Immunotherapy Segment Projected to be the Fastest Growing Segment” https://t.co/FC1n10wV6o https:…
4hreplyretweetfavorite
Interasma RT @Aller_MD: Top story: The Myth of Drug Expiration Dates - ProPublica https://t.co/8bS0FafKTF, see more https://t.co/jgCeENQuZt
4hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma